-
Something wrong with this record ?
Recent-onset dilated cardiomyopathy associated with Borrelia burgdorferi infection
P. Kuchynka, T. Palecek, S. Havranek, I. Vitkova, E. Nemecek, R. Trckova, D. Berenová, D. Krsek, J. Podzimkova, M. Fikrle, BA. Danek, A. Linhart,
Language English Country Germany
Document type Controlled Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't
NLK
ProQuest Central
from 1997-02-01 to 1 year ago
Medline Complete (EBSCOhost)
from 2005-02-01 to 1 year ago
Health & Medicine (ProQuest)
from 1997-02-01 to 1 year ago
- MeSH
- Anti-Bacterial Agents administration & dosage MeSH
- Endocarditis, Bacterial diagnosis drug therapy microbiology MeSH
- Borrelia burgdorferi isolation & purification MeSH
- Ceftriaxone administration & dosage MeSH
- Cardiomyopathy, Dilated diagnosis drug therapy microbiology MeSH
- Injections, Intravenous MeSH
- Cardiotonic Agents administration & dosage MeSH
- Drug Therapy, Combination methods MeSH
- Middle Aged MeSH
- Humans MeSH
- Lyme Disease diagnosis drug therapy microbiology MeSH
- Treatment Outcome MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Controlled Clinical Trial MeSH
- Research Support, Non-U.S. Gov't MeSH
BACKGROUND: Several recent small studies have suggested a causal link between Lyme disease and dilated cardiomyopathy (DCM) by demonstrating the presence of the Borrelia burgdorferi (Bb) genome in the myocardium of patients with recent-onset DCM. The aim of this study was to further investigate the effect of targeted antibiotic treatment of Bb-related recent-onset DCM in a larger cohort of patients. PATIENTS AND METHODS: We performed endomyocardial biopsy (EMB) in 110 individuals (53 ± 11 years, 34 women) with recent-onset unexplained DCM, and detected the Bb genome in 22 (20 %) subjects. Bb-positive patients were subsequently treated with intravenous ceftriaxone for 21 days in addition to conventional heart failure medication. RESULTS: At the 1-year follow-up, a significant improvement in left ventricular (LV) ejection fraction (26 ± 6 vs. 44 ± 12 %; p < 0.01) and a decrease in LV end-diastolic (69 ± 7 vs. 63 ± 11 mm; p < 0.01) and end-systolic (61 ± 9 vs. 52 ± 4 mm; p < 0.01) diameters were documented. Moreover, a significant improvement in heart failure symptoms (NYHA class 3.4 ± 0.6 vs. 1.5 ± 0.7; p < 0.01) was also observed. CONCLUSION: Targeted antibiotic treatment of Bb-related recent-onset DCM in addition to conventional heart failure therapy is associated with favorable cardiac remodeling and improvement of heart failure symptoms.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc16020832
- 003
- CZ-PrNML
- 005
- 20240911144731.0
- 007
- ta
- 008
- 160722s2015 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s00059-015-4308-1 $2 doi
- 024 7_
- $a 10.1007/s00059-015-4308-1 $2 doi
- 035 __
- $a (PubMed)25939436
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Kuchynka, Petr $u 2nd Department of Medicine-Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, U Nemocnice 2, 128 08, Prague 2, Czech Republic. International Clinical Research Center, St. Anne's University Hospital in Brno, Brno, Czech Republic.
- 245 10
- $a Recent-onset dilated cardiomyopathy associated with Borrelia burgdorferi infection / $c P. Kuchynka, T. Palecek, S. Havranek, I. Vitkova, E. Nemecek, R. Trckova, D. Berenová, D. Krsek, J. Podzimkova, M. Fikrle, BA. Danek, A. Linhart,
- 520 9_
- $a BACKGROUND: Several recent small studies have suggested a causal link between Lyme disease and dilated cardiomyopathy (DCM) by demonstrating the presence of the Borrelia burgdorferi (Bb) genome in the myocardium of patients with recent-onset DCM. The aim of this study was to further investigate the effect of targeted antibiotic treatment of Bb-related recent-onset DCM in a larger cohort of patients. PATIENTS AND METHODS: We performed endomyocardial biopsy (EMB) in 110 individuals (53 ± 11 years, 34 women) with recent-onset unexplained DCM, and detected the Bb genome in 22 (20 %) subjects. Bb-positive patients were subsequently treated with intravenous ceftriaxone for 21 days in addition to conventional heart failure medication. RESULTS: At the 1-year follow-up, a significant improvement in left ventricular (LV) ejection fraction (26 ± 6 vs. 44 ± 12 %; p < 0.01) and a decrease in LV end-diastolic (69 ± 7 vs. 63 ± 11 mm; p < 0.01) and end-systolic (61 ± 9 vs. 52 ± 4 mm; p < 0.01) diameters were documented. Moreover, a significant improvement in heart failure symptoms (NYHA class 3.4 ± 0.6 vs. 1.5 ± 0.7; p < 0.01) was also observed. CONCLUSION: Targeted antibiotic treatment of Bb-related recent-onset DCM in addition to conventional heart failure therapy is associated with favorable cardiac remodeling and improvement of heart failure symptoms.
- 650 _2
- $a antibakteriální látky $x aplikace a dávkování $7 D000900
- 650 _2
- $a Borrelia burgdorferi $x izolace a purifikace $7 D025065
- 650 _2
- $a dilatační kardiomyopatie $x diagnóza $x farmakoterapie $x mikrobiologie $7 D002311
- 650 _2
- $a kardiotonika $x aplikace a dávkování $7 D002316
- 650 _2
- $a ceftriaxon $x aplikace a dávkování $7 D002443
- 650 _2
- $a kombinovaná farmakoterapie $x metody $7 D004359
- 650 _2
- $a bakteriální endokarditida $x diagnóza $x farmakoterapie $x mikrobiologie $7 D004697
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a injekce intravenózní $7 D007275
- 650 _2
- $a lymeská nemoc $x diagnóza $x farmakoterapie $x mikrobiologie $7 D008193
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a klinické zkoušky kontrolované $7 D018848
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Palecek, Tomas $u 2nd Department of Medicine-Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, U Nemocnice 2, 128 08, Prague 2, Czech Republic. tpalec@lf1.cuni.cz. International Clinical Research Center, St. Anne's University Hospital in Brno, Brno, Czech Republic. tpalec@lf1.cuni.cz.
- 700 1_
- $a Havranek, Stepan $u 2nd Department of Medicine-Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, U Nemocnice 2, 128 08, Prague 2, Czech Republic.
- 700 1_
- $a Vitkova, Ivana $u Institute of Pathology, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Prague, Czech Republic.
- 700 1_
- $a Nemecek, Eduard $u 2nd Department of Medicine-Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, U Nemocnice 2, 128 08, Prague 2, Czech Republic.
- 700 1_
- $a Trckova, Radka $u 2nd Department of Medicine-Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, U Nemocnice 2, 128 08, Prague 2, Czech Republic.
- 700 1_
- $a Berenová, Dagmar $u The National Institute of Public Health, Prague, Czech Republic. $7 xx0210361
- 700 1_
- $a Krsek, Daniel $u The National Institute of Public Health, Prague, Czech Republic. $7 xx0210362
- 700 1_
- $a Podzimkova, Jana $u 2nd Department of Medicine-Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, U Nemocnice 2, 128 08, Prague 2, Czech Republic.
- 700 1_
- $a Fikrle, Michal $u 2nd Department of Medicine-Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, U Nemocnice 2, 128 08, Prague 2, Czech Republic. $7 xx0322391
- 700 1_
- $a Danek, Barbara Anna $u 2nd Department of Medicine-Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, U Nemocnice 2, 128 08, Prague 2, Czech Republic. $7 xx0313114
- 700 1_
- $a Linhart, Ales $u 2nd Department of Medicine-Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, U Nemocnice 2, 128 08, Prague 2, Czech Republic.
- 773 0_
- $w MED00002031 $t Herz $x 1615-6692 $g Roč. 40, č. 6 (2015), s. 892-7
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/25939436 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20160722 $b ABA008
- 991 __
- $a 20240911144727 $b ABA008
- 999 __
- $a ok $b bmc $g 1155502 $s 945360
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2015 $b 40 $c 6 $d 892-7 $e 20150505 $i 1615-6692 $m Herz $n Herz $x MED00002031
- LZP __
- $a Pubmed-20160722
